YopH of Yersinia Pseudotuberculosis Interrupts Early Phosphotyrosine Signalling Associated with Phagocytosis
Overview
Molecular Biology
Affiliations
The PTPase YopH of Yersinia is essential to the ability of these bacteria to block phagocytosis. Wild-type Yersinia pseudotuberculosis, but not the yopH mutant strain, resisted phagocytosis by J774 cells. Ingestion of a yopH mutant was dependent on tyrosine kinase activity. Transcomplementation with wild-type yopH restored the anti-phagocytic effect, whereas introduction of the gene encoding the catalytically inactive yopHC403A was without effect. The PTPase inhibitor orthovanadate impaired the anti-phagocytic effect of the wild-type strain, further demonstrating the importance of bacteria-derived PTPase activity for this event. The ability to resist phagocytosis indicates that the effect of the bacterium is immediately exerted when it becomes associated with the phagocyte. Within 30 s after the onset of infection, wild-type Y. pseudotuberculosis caused a YopH-dependent dephosphorylation of phosphotyrosine proteins in J774 cells. Furthermore, interaction of the cells with phagocytosable strains led to a rapid and transient increase in tyrosine phosphorylation of paxillin and some other proteins, an event dependent on the presence of the bacterial surface-located protein invasin. Co-infection with the phagocytosable strain and the wild-type strain abolished the induction of tyrosine phosphorylation. Taken together, the present findings demonstrate an immediate YopH-mediated dephosphorylation of macrophage phosphotyrosine proteins, suggesting that this PTPase acts by preventing early phagocytosis-linked signalling in the phagocyte.
Citric Acid Controls the Activity of YopH Bacterial Tyrosine Phosphatase.
Styszko J, Kostrzewa T, Gorska-Ponikowska M, Kuban-Jankowska A Drug Des Devel Ther. 2024; 18:1165-1174.
PMID: 38623566 PMC: 11018125. DOI: 10.2147/DDDT.S444500.
Pathogenicity and virulence of .
Seabaugh J, Anderson D Virulence. 2024; 15(1):2316439.
PMID: 38389313 PMC: 10896167. DOI: 10.1080/21505594.2024.2316439.
Host-directed therapy for bacterial infections -Modulation of the phagolysosome pathway.
Taya T, Teruyama F, Gojo S Front Immunol. 2023; 14:1227467.
PMID: 37841276 PMC: 10570837. DOI: 10.3389/fimmu.2023.1227467.
Type III-Secreted Effectors Evade the Caspase-4 Inflammasome in Human Cells.
Zhang J, Brodsky I, Shin S bioRxiv. 2023; .
PMID: 36747770 PMC: 9900831. DOI: 10.1101/2023.01.24.525473.
Fasciano A, Dasanayake G, Estes M, Zachos N, Breault D, Isberg R Gut Microbes. 2021; 13(1):1988390.
PMID: 34793276 PMC: 8604394. DOI: 10.1080/19490976.2021.1988390.